O
TCRR

OrbiMed’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

OrbiMed’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-249,279
Closed -$5.5M – 179
2021
Q1 		$5.5M Hold
249,279
– – 0.05% 139
2020
Q4 		$7.71M Buy
+249,279
New +$6.3M 0.07% 130

Other funds holding TCRR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

OrbiMed's TCRR Position: Q2 2021 in Review

OrbiMed sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2021, closing a stake of 249,279 shares — an estimated $5.5M sold.

OrbiMed first reported a position in TCRR in Q4 2020 and held it in 2 quarters. The position peaked at $7.71M in Q4 2020. 119 funds tracked by Wall St. Rank hold TCRR as of Q2 2021.

  • OrbiMed reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • OrbiMed sold 249,279 TCR2 Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $5.5M.
  • OrbiMed first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • OrbiMed's TCR2 Therapeutics Inc. Common Stock position peaked at $7.71M in Q4 2020.
  • 119 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2021.

Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.